Artal Group’s BioNTech BNTX Stock Holding History

Artal Group’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-150,000	Closed	-$10M	–	141
2020 Q2	$10M	Buy	+150,000	New	+$7.49M	0.28%	69

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Artal Group's BNTX Position: Q2 2021 in Review

Artal Group sold out of BioNTech (BNTX) in Q2 2021, closing a stake of 900,000 shares — an estimated $98.3M sold.

Artal Group first reported a position in BNTX in Q4 2019 and held it in 6 quarters. The position peaked at $133M in Q2 2020. 283 funds tracked by Wall St. Rank hold BNTX as of Q2 2021.

Artal Group reported no remaining BioNTech position as of Q2 2021 after selling out during the quarter.
Artal Group sold 900,000 BioNTech shares in Q2 2021, an estimated $98.3M.
Artal Group first reported a position in BioNTech in Q4 2019 and held it in 6 quarters.
Artal Group's BioNTech position peaked at $133M in Q2 2020.
283 funds tracked by Wall St. Rank held BioNTech as of Q2 2021.

Based on Artal Group's 13F filing for Q2 2021, filed 13 Aug 2021.